Binding Site is a specialised diagnostics company producing protein tests for diagnosis of certain blood cancer diseases as well as immunological disorders. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

The UK head office houses all product development, manufacturing, global distribution and marketing. Worldwide customer support is also provided by a further 7 offices in the US and Europe.

Binding Site was acquired by Nordic CapitalĀ Fund VII in 2011.

Key Information

Revenues Icon

Revenues 2016*

EUR 120 million

Employees Icon

Employees

730

Ownership Icon

Ownership

Nordic Capital Fund VII, controlling shareholding

Head Office Icon

Head office

Birmingham, UK

Investment Icon

Investment date

2011

* Reported